197 related articles for article (PubMed ID: 19220420)
1. Rapid infusion of rituximab over 60 min.
Tuthill M; Crook T; Corbet T; King J; Webb A
Eur J Haematol; 2009 Apr; 82(4):322-5. PubMed ID: 19220420
[TBL] [Abstract][Full Text] [Related]
2. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function.
Siano M; Lerch E; Negretti L; Zucca E; Rodriguez-Abreu D; Oberson M; Leoncini L; Mora O; Sessa C; Gallino A; Ghielmini M
Clin Cancer Res; 2008 Dec; 14(23):7935-9. PubMed ID: 19047125
[TBL] [Abstract][Full Text] [Related]
4. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and safety of rituximab (MabThera).
Kimby E
Cancer Treat Rev; 2005 Oct; 31(6):456-73. PubMed ID: 16054760
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety and feasibility of rapid rituximab infusion.
Lang D; Prouse J; Barry F; Catherwood A; Chaplin K; Elliott L; Greco K; McGahey W; Nilsen J; Singhal N
Asia Pac J Clin Oncol; 2012 Mar; 8(1):71-5. PubMed ID: 22369446
[TBL] [Abstract][Full Text] [Related]
7. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
8. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits.
Swan JT; Zaghloul HA; Cox JE; Murillo JR
Pharmacotherapy; 2014 Jul; 34(7):686-94. PubMed ID: 24706572
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
[TBL] [Abstract][Full Text] [Related]
11. Rapid-infusion rituximab in lymphoma treatment.
Provencio M; Cerdeira S; Bonilla F; Sánchez A; España P
Ann Oncol; 2006 Jun; 17(6):1027-8. PubMed ID: 16322113
[No Abstract] [Full Text] [Related]
12. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
Salar A; Casao D; Cervera M; Pedro C; Calafell M; Abella E; Alvarez-Larrán A; Besses C
Eur J Haematol; 2006 Oct; 77(4):338-40. PubMed ID: 16856919
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Chung L; Genovese MC; Fiorentino DF
Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
[TBL] [Abstract][Full Text] [Related]
14. Infusion reactions: diagnosis, assessment, and management.
Vogel WH
Clin J Oncol Nurs; 2010 Apr; 14(2):E10-21. PubMed ID: 20350882
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous B-cell lymphoma treated with rituximab infusions.
Schneider LA
Acta Derm Venereol; 2006; 86(6):550-1. PubMed ID: 17106608
[No Abstract] [Full Text] [Related]
16. Rapid infliximab infusions in pediatric inflammatory bowel disease.
Yeckes AR; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):151-4. PubMed ID: 19516188
[TBL] [Abstract][Full Text] [Related]
17. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
[TBL] [Abstract][Full Text] [Related]
18. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
Abasq C; Duval-Modeste AB; Courville P; Joly P
Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
[No Abstract] [Full Text] [Related]
19. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
20. Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
Oribe N; Tanimoto TE; Shimoda K; Hikiji W; Mitsugi K; Takase K; Henzan H; Numata A; Miyamoto T; Fukuda T; Nagafuji K; Harada M
Haematologica; 2004 Jun; 89(6 Suppl):EIM14. PubMed ID: 15194556
[No Abstract] [Full Text] [Related]
[Next] [New Search]